Objective: Investigate the role of S1R in the mechanism of action of pridopidine.
Background: Sigma-1 receptor (S1R) is an ER chaperone protein involved in neuromodulation and neuroplasticity. Pridopidine is a selective S1R agonist small molecule currently in clinical development for Huntington disease by Teva Pharmaceuticals Ltd.
Design/Methods: Transcriptomic analysis of WT and S1R-deficient mice treated with increasing concentrations of pridopidine (0, 0.3, 3, 30, or 60 mg/kg) for 10 days. Prefrontal cortex, striatum and hippocampus tissues were collected and profiled via RNAseq.